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K20 is a novel amphiphilic antifungal aminoglycoside that is synthetically derived from the
antibiotic kanamycin A. Reported here are investigations of K20’s antimicrobial activities,
cytotoxicity, and fungicidal mechanism of action. In vitro growth inhibitory activities against
a variety of human and plant pathogenic yeasts, filamentous fungi, and bacteria were
determined using microbroth dilution assays and time-kill curve analyses, and hemolytic
and animal cell cytotoxic activities were determined. Effects on Cryptococcus neoformans
H-99 infectivity were determined with a preventive murine lung infection model. The
antifungal mechanism of action was studied using intact fungal cells, yeast lipid mutants,
and small unilamellar lipid vesicles. K20 exhibited broad-spectrum in vitro antifungal
activities but not antibacterial activities. Pulmonary, single dose-administration of K20
reduced C. neoformans lung infection rates 4-fold compared to controls. Hemolysis and
half-maximal cytotoxicities of mammalian cells occurred at concentrations that were 10 to
32-fold higher than fungicidal MICs. With fluorescein isothiocyanate (FITC), 20–25mg/L
K20 caused staining of >95% of C. neoformans and Fusarium graminearum cells
and at 31.3mg/L caused rapid leakage (30–80% in 15min) of calcein from preloaded
small unilamellar lipid vesicles. K20 appears to be a broad-spectrum fungicide, capable
of reducing the infectivity of C. neoformans, and exhibits low hemolytic activity and
mammalian cell toxicity. It perturbs the plasma membrane by mechanisms that are lipid
modulated. K20 is a novel amphiphilic aminoglycoside amenable to scalable production
and a potential lead antifungal for therapeutic and crop protection applications.
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INTRODUCTION
Fungal diseases are major threats to human health and food
security (Strange and Scott, 2005; Fisher et al., 2012). Invasive
human fungal infections such as cryptococcal meningitis caused
by Cryptococcus neoformans have increased due to the rising
number of immunocompromised individuals (Park et al., 2009;
Shirley and Baddley, 2009). Fungal crop diseases such as wheat
head blight or scab (caused by Fusarium graminearum) and stem
rust (caused by Puccinia graminis) create large economic losses
and threats to the world’s food supplies (Strange and Scott, 2005).
Conventional antifungals such as amphotericin B, and azoles are
still used to treat invasive fungal infections (Jarvis and Harrison,
2008) and fungicidal triazoles and strobulins continue to be used
in massive quantities for wheat and other major crops (Fisher
et al., 2012; Strange and Scott, 2005). Their effectiveness how-
ever grows increasingly limited by fungal resistance, host side
effects, and ecosystem disturbances (Fisher et al., 2012; Strange
and Scott, 2005). A consequence is a growing need to develop
novel antifungals that are safe and effective.
Aminoglycosides are compounds having two or more amino
sugars bound to an aminoacyclitol ring via glycosidic bonds.
Many are used therapeutically against bacterial infections of
humans and animals (Jarvis and Harrison, 2008). Among
them, kanamycin A, produced by the soil microbe Streptomyces
kanamyceticus, is one of the most successful (Umezawa et al.,
1957; Begg and Barclay, 1995; Vakulenko and Mobashery, 2003).
Kanamycin A is structurally based on neamine rings I and II
with an attached ring III of O-6-linked kanosamine (Figure 1).
Most bind to the prokaryotic 16S rRNA in the decoding region
A site, leading to the formation of defective cell proteins. Despite
being mainly antibacterial, certain classical aminoglycosides are
also found to inhibit crop pathogenic fungal-like heterokonts (Lee
et al., 2005) and certain structurally unusual ones inhibit yeasts
and protozoans (Wilhelm et al., 1978). Previously, we reported
on a novel aminoglycoside analog of kanamycin B, FG08, with
broad-spectrum antifungal properties that did not inhibit tested
bacterial and mammalian cells (Figure 1) (Chang et al., 2010).
FG08 differs from kanamycin B by substitution of a C8 alkyl
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FIGURE 1 | Structures of aminoglycosides FG08, kanamycin A, and K20.
chain at the O-4′′position of ring III to impart amphiphilic
properties (Figure 1) (Chang et al., 2010). However, as a lead
antifungal agent, FG08 is limited. Incorporation of the C8 alkyl
chain at the kanamycin B O-4′′ position is difficult and the prod-
uct yield is low. These shortcomings prompted the search for
similar amphiphilic aminoglycosides using alternative synthetic
approaches (Chang and Takemoto, 2014). From this effort, a
novel and scalable aminoglycoside, K20, derived from kanamycin
A was discovered that structurally resembled FG08 and that also
possessed antifungal activity (Chang and Takemoto, 2012, 2014).
In the current study, K20’s antifungal activities are more thor-
oughly examined, and its animal cell cytotoxicity and hemolytic
capabilities were determined. K20’s antifungal mechanism of
action was determined using intact fungal cells and model lipid
bilayer membranes. Like FG08, K20 exhibited growth inhibitory
activities against a broad range of fungal species, but not against
bacteria, and it was not hemolytic or cytotoxic at concentrations
that inhibit fungi. K20’s primary mechanism of action is shown to
involve perturbation of plasma membrane permeability. Finally,
in proof of concept experiments, K20 was observed to reduce the
infectivity of C. neoformans in a preventive murine lung infection
model,
MATERIALS AND METHODS
K20 AND OTHER ANTIMICROBIALS
K20 was synthesized from kanamycin A (Chang and Takemoto,
2014). Briefly, tetra-di-tert-butyl carbonate (Boc)-protected
kanamycin A was stirred overnight with octanesulfonyl chloride
in anhydrous pyridine at 0◦C. The mixture was then stirred at
room temperature for 6 days, heated and incubated at 40◦C for
1 day, and then concentrated to an oily crude product. Water
(500mL) was added to the residue material, and the mixture was
stirred for 1 day. The suspension was extracted with ethyl acetate
in a separatory funnel, washed twice with 1.0 N HCl and once
with water. The wash sequence was repeated 3 to 4 times, and
the final organic layer was filtered and evaporated. The residue
was treated with trifluoroacetic acid/dichloromethane (1:4) and
stirred overnight. The solvents were removed, water added and
the material evaporated to remove residual acid. The crude prod-
uct was dissolved in water and washed repeatedly with ethyl
acetate until the aqueous fraction was clear. The aqueous solution
was concentrated and passed through a column of Dowex1X-8
(Cl-form). K20 in highly pure form was recovered (overall yield
of 40%) after evaporation and stored as a solid at 5◦C. K20 was
characterized by 1H NMR and 13C NMR (using a Joel 300MHz
NMR spectrometer) and mass spectrometry [using a Waters
GCT (2008) High resolution mass spectrometer at the High
Resolution Mass Spectrometry Facility, University of California,
Riverside, USA]. Correlation Spectroscopy (COSY) and edited
Heteronuclear Single Quantum Correlation (HSQC) were used
for H-H and H-C correlation, respectively (see Supplementary
Material). For bioactivity tests and mechanism of action stud-
ies, a 10 mg/mL stock solution was prepared in twice distilled
water and stored at 5◦C. FG08 was synthesized as previously
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described (Chang et al., 2010), and kanamycin A was purchased
(Changzhou Zhongtian Chemical Co. LTD., Changzhou, PRC).
ORGANISMS AND CULTURE CONDITIONS
Fusarium graminearum strain B4-5A was obtained from the
Small Grain Pathology Program, University of Minnesota,
Minneapolis MN, USA. E. coli TG1, S. aureus ATCC6538,
M. luteus ATCC10240, C.albicans ATCC10231(azole-resistant),
C. albicans ATCC64124 (azole–resistant), and C. albicans ATCC
MYA-2876 (azole sensitive) were obtained from the American
Type Culture Collection (Manassas, VA, USA). Saccharomyces
cerevisiae strains W303C (MATa ade2 his3 leu2 trp1 ura3) and
isogenic sphingolipid biosynthesis mutant strains W303-syr2
(MATα ade2 his3 leu2 trp1 ura3 syr2 (sur2)::URA3), W303-
elo3 (MATα ade2 his3 leu2 trp1 ura3 elo2::HIS3), and W303-
syr4(ipt1)(MATα ade2 his3 leu2 trp1 ura3 syr4 (ipt1)::URA3)
were previously described (Stock et al., 2000). Phenotypically,
these mutants lack sensitivity to the antifungal syringomycin E—
a membrane lipidic pore forming cyclic lipodespsipeptide (Stock
et al., 2000). C. neoformans H99 was obtained from Dr. J. Perfect
(Duke University Medical Center, Durham, NC, USA). C. neofor-
mans 94-2586,C. neoformans 90-26,C. tropicalis 95-41,C. albicans
94-2181, C. albicans B-311, C. rugosa 95-967, C. pseudotropicalis
YOGI, andC. lusitaniae 95-767 were obtained from the laboratory
culture collection of Dr. Kevin Sorensen (Snow College, Ephraim,
Utah, USA). Aspergillus flavus, and F. oxysporum were obtained
from Dr. Bradley Kropp (Utah State University, Logan, UT, USA)
and A. niger and Botrytis alcada were obtained from Dr. Claudia
Nischwitz (Utah State University, Logan, UT, USA). Filamentous
fungi and yeast strains were maintained on potato dextrose agar
(PDA) and cultivated at 28◦C in potato dextrose broth (PDB)
or at 35◦C with RPMI 1640 (with L-glutamine, without sodium
bicarbonate (Sigma-Aldrich Chemical Co., St. Louis, MO, USA)
buffered to pH 7.0 with 0.165Mmorpholinepropanesulfonic acid
(MOPS). Bacterial strains were grown at 37◦C for 24 h on Luria-
Bertani (LB) medium (Sambrook et al., 1989) except for S. aureus
ATCC6538 which was grown onMueller-Hinton medium (Difco,
BD, Franklin Lakes, NJ, USA).
FUNGAL GROWTH INHIBITION ASSAYS
Minimal inhibitory concentration (MIC) and minimal fungi-
cidal concentration (MFC) values of K20 against yeast strains
were determined using microbroth dilution assays in 96-well
uncoated polystyrene microtiter plates (Corning Costar, Corning,
NY, USA) as described in the M27-A3 reference methods of the
Clinical and Laboratory Standards Institute (CLSI) (formerly the
National Committee for Clinical Laboratory Standards) (NCCLS,
2002) with minor modifications. Modifications included growing
yeast cell inocula in RPMI 1640 medium for 48 h at 35◦C and
suspending fresh-grown inocula to a concentration of 5 × 104
cells/mL (determined by hemocytometer cell counting) in fresh
RPMI 1640 for the assays. All yeast cell suspensions (100μL)
containing 0.48 to 250mg/L of serial diluted K20 except for
C. neoformans (with 0.25–128mg/L of K20) were added to the
wells of a 96-well microtiter plate and incubated for 48 h at 35◦C.
Controls were no yeast cells and no K20 added to separate wells.
MFC values were determined as the occurrence of fewer than 3
colonies after plating 5μL of the cleared microtiter plate wells
fromMIC tests on Sabouraud’s dextrose agarmedium (Difco, BD,
Franklin Lakes, NJ, USA). Each test was performed in triplicate.
For in vitro antifungal activities against F. graminearum B4-5A,
F. oxysporum, A. flavus, A. niger, and Botrytis alcada, spores were
prepared as described previously (Lay et al., 2003). Spores were
isolated from sporulating cultures growing in PDB medium by
filtration through sterile glass wool. Microbroth dilution assays
for determination of MICs were conducted using the M38-A2
protocols of the CLSI (NCCLS, 2008) with minor modification.
Serial dilutions of K20 weremade in uncoated polystyrene 96-well
plates in the range of 0.48–250mg/L using RPMI 1640 medium
and spore suspensions were added to make a final concentration
of 5 × 105 CFU/mL. The plates were incubated at 35◦C for 72 h
except for tests with F. graminearum B4-5A which were incubated
for 48 h. MIC values were determined as the lowest concentra-
tion of compounds showing optically clear solutions by visual
inspection of the plate wells (NCCLS, 2002, 2008). Each test was
performed in triplicate. Disk diffusion assays of yeast strains were
performed as previously described (Chang et al., 2010). Cell sus-
pensions (0.5mL)were spread–plated onto potato-dextrose agar
(PDA) medium and air-dried for 5min. Eight microliter aliquots
of K20 (1–10mg/mL in water) were applied to 0.6 cm diameter
paper disks placed on the agar surfaces, and the plates were incu-
bated for 24–48 h at 28◦C. These amounts of K20 provided visible
and measurable zones of growth inhibition around the disks as
previously determined for FG08 (Chang et al., 2010).
BACTERIAL GROWTH INHIBITION ASSAYS
The in vitro effects of K20 on the growth of bacterial species E. coli
TG1, M. luteusATCC10240 and S. aureusATCC6538 were assayed
in 96-well uncoated polystyrene microtiter plates and MICs were
determined using CLSI protocols with modification (NCCLS,
1993). Cells were grown overnight in Luria-Bertani medium and
diluted to a concentration of 1 × 104 CFU/mL. Ten microliter
of the diluted overnight culture were then added to 190μL of
Luria–Bertani medium containing K20 at concentrations rang-
ing between 0.48 and 250mg/L. Controls were bacterial cells only
and no K20 added to separate wells. The plates were incubated
at 37◦C without shaking for 24 h before determination of MICs.
Experiments were performed in triplicate.
ANTIFUNGAL CARRYOVER AND TIME-KILL CURVE ANALYSES
Antifungal carryover was determined as described by Klepser
et al. (2000). C. neoformans H99 cell suspensions were prepared
in sterile water to yield 1 × 105 CFU/mL. One hundred micro-
liter of each suspension was added to 900μL of sterile water
(control) or to sterile water containing K20 at concentrations of
2, 4, and 8mg/L, equal to 0.5, 1, and 2 times the MIC, respec-
tively. Immediately after addition of fungal suspension, 100μL of
suspension was removed and spread-plated on PDA for colony
count determination. Antifungal carryover was indicated when a
reduction in colony counts of >25% compared to controls was
observed. Time-kill curves were generated as described (Klepser
et al., 2000) with modifications. Colonies from 24 to 48 h cultures
were suspended in 9mL sterile water and adjusted to 1 × 108
CFU/mL. One milliliter of the adjusted fungal suspension was
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then added to 1 L of either PDB growth medium alone (control)
or a solution of PDB and K20 at concentrations of 2, 4 or 8mg/L.
Fifty milliliter aliquots of culture suspensions in 125-mL capacity
Erlenmeyer flasks were incubated in a water bath shaker (Model
G76, New Brunswick Scientific, NJ, USA) with agitation at 35◦C.
At 0, 4, 9, 24, and 48 h, 100μL aliquots were removed from each
solution and serially diluted 10-fold in sterile water. One hundred
microliter volumes of each dilution were spread on agar surfaces
of potato dextrose agar [PDB containing agar (2%, wt/vol)] plates
to allow growth. Colony counts were determined after incuba-
tion for 48 h. The experiment was performed in triplicate. The
lower limit for accurate and reproducible quantification was 50
CFU/mL (Klepser et al., 2000).
HEMOLYTIC ACTIVITY
Hemolytic activity was determined using previously described
methods (Dartois et al., 2005) with modification. Sheep erythro-
cytes were obtained by centrifuging sheep whole blood at 1000×
g, washing four times with phosphate-buffered saline (PBS), and
resuspending in PBS to a final concentration of 108 erythro-
cytes/mL. The erythrocyte suspension (80μL) was added to wells
of a 96-well polystyrene microtiter plate containing 20μL of
serially diluted K20 (1.0–0.015.1 g/L) in water. The plate was incu-
bated at 37◦C for 60min. Wells with added deionized water and
Triton X-100 (1% v/v) served as negative (blank) and positive
controls, respectively. The A490 values of each well were measured
using a BioTek Synergy 4 microplate reader (BioTek Instruments
Inc., Winooski, VT, USA). Percent hemolysis was calculated using
the following equation: % hemolysis= [(A490 of sample)− (A490
of blank)]× 100/(A490 of positive control). Fifty percent hemoly-
sis (HC50) values were calculated as K20 concentrations that lyse
50% of the erythrocytes.
IN VITRO CYTOTOXICITY ASSAYS
Cytotoxicity assays were performed as previously described for
FG08 (Shrestha et al., 2013). The C8161.9 melanoma cell line was
a gift from Dr. Danny R. Welch, University of Kansas, Lawrence,
KS (USA). Fibroblast cell line NIH3T3 (ATCC® CRL-1658™) was
obtained from the American Type Culture Collection (Manassas,
VA, USA.)
C8161.9 cells were grown in DMEM/Ham’s F12 (1:1) contain-
ing 10% fetal bovine serum (FBS). NIH3T3 cells were grown in
DMEM (high glucose) medium containing 10% FBS in Corning
Cell Bind flasks. The confluent cells were then trypsinized with
0.25%, w/v trypsin and resuspended in fresh medium (DMEM).
The cells were transferred into 96-well uncoated polystyrene
microtiter plates at a density of 2 × 105 cells/mL. K20 was added
at final concentrations of 10, 20, 50, 100, and 250 mg/L or
an equivalent volume of sterile double distilled water (nega-
tive control). The cells were incubated for 24 h at 37◦C with
5% CO2 in a humidified incubator. To evaluate cytotoxicity,
each well was treated with 10μL of 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide (MTT) (Sigma-Aldrich, St.
Louis, MO USA) for 4 h. In living cells, mitochondrial reduc-
tases convert the MTT tetrazolium to formazan, which precipi-
tates. Formazan was dissolved adding 10% (wt/vol) NaDodSO4
in 0.01M HCl and quantified at A570 using a BioTek Synergy4
microplate reader (BioTek Instruments Inc., Winooski, VT, USA).
Triton X-100® (1%, vol/vol) gave complete loss of cell viability
and was used as the positive control. The ratios of A570 values
for K20 treated cells to the A570 values for the untreated cells
were used to calculate % cell survival. Standard deviations were
determined from data sets of three separate experiments.
MEMBRANE PERMEABILIZATION
C. neoformans H99 (5 × 105 CFU/mL) or F. graminearum (5 ×
105 conidia/mL) were grown for 18 h in PDB with continu-
ous agitation. Aliquots (500μL) were taken and centrifuged for
2min at 10,000× g. The fungal pellet was suspended in 10mM
HEPES, pH 7.4, centrifuged again, and suspended in 500μL dis-
tilled water (Chang et al., 2010). C. neoformans H99 cells were
exposed to 4, 8, and 25 mg/L K20 and F. graminearum B4-5A
hyphae to 7.8, 15.6, and 32mg/L K20 for 1 h at 28◦C with contin-
uous agitation. The K20 treated fungi were assessed 10min after
addition of fluorescein isothiocyanate (FITC) (10mg/mL stock in
acetone) (Sigma-Aldrich Chemical Co., St. Louis, MO, USA) to
6mg/L as previously described (Shrestha et al., 2013) with slight
modification. Negative (water) and positive (Triton X-100® 1%,
vol/vol) treatment controls were also prepared. Glass slides were
prepared with 10μL of each mixture and observed in dark-field
and fluorescence (using an Olympus MWIB filter, excitation, and
emission wavelength 488–512 nm) modes with an Olympus IX81
fluorescence microscope (Olympus, Center Valley, PA, USA). Dye
uptake of C. neoformans H99 cells was quantitated as previously
described (Shrestha et al., 2013) and of F. graminearum B4-5A by
qualitative estimates from visual inspection. Data were obtained
from at least three independent experiments.
CALCEIN RELEASE FROM SMALL UNILAMELLAR VESICLES (SUVs)
Lipids (from Sigma-Aldrich Chemical Co., St. Louis, MO
USA) were phosphatidylcholine from Glycine max (PC), L-α-
phosphatidylethanolamine from E. coli (PE), L-α- phosphatidyli-
nositol (Na salt) from G. max (PI), and ergosterol. Model lipid
bilayer membrane SUVs were prepared by dissolving mixtures of
lipids in chloroform/methanol (2:1, vol/vol). The mixtures were
PC, PE, PI, and ergosterol (5:4:1:2 ratios by wt) and PC and ergos-
terol (10:1 ratio by wt) to mimic the lipid compositions of fungal
plasma membranes (Makovitzki et al., 2006; Lee et al., 2009).
The organic solvents were evaporated with nitrogen gas and the
lipid mixtures dried under vacuum. The dried lipid films were
rehydrated in HEPES buffer (10mM HEPES, 150mM NaCl, pH
7.4) and sonicated to generate SUVs with lipid concentrations at
10mg/mL. Lipid films were prepared as described above and were
suspended in 10mM HEPES, 150mM NaCl, pH 7.4, and 60mM
calcein (self-quenching concentration) (Makovitzki et al., 2006).
Liposome suspensions were sonicated for 2min using a sonicator
(Sonicator™ Heat System, W-220F, Ultrasonics, NY, USA). The
free calcein was removed by gel filtration through a Sephadex G-
50 column. K20 at concentrations of 31.3 [at or near the MICs
for most fungi tested (Table 1)], 62.2, and 125 mg/L (2- and 4-
fold higher, respectively, than the initial concentration) was added
to the calcein-loaded SUV suspensions (lipid concentration of
6 to 10μM), and calcein leakage was followed by measuring
fluorescence using a BioTek Synergy HT microplate reader at
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Table 1 | Minimal inhibitory concentrations of K20 and kanamycinA
against bacteria and fungi.
Organism MIC (mg/L)a
K20 Kanamycin ITC FLC
YEASTS
C. neoformans H99 3.9–7.8 >125b 1.56 1.56
C. neoformans 94-2586 3.9–7.8 >125b 0.06 1.56
C.neoformans 90-26 3.9–7.8 >250 0.37 >0.195
C. pseudotropicalis YOGI 15.6 >250 0.125–0.8 ndc
C. lusitaniae 95-767 >7.8 >250 0.2 1.56
C. rugosa 95-967 15.6 >250 0.12 >0.78
C. tropicalis 95-41 15.6 >250b >25 >25
C. albicans 10231 15.6 >250b 0.75 25
C. albicans 64124(R)d 31.3 >500b >64 >200
C. albicans MYA 2876 (S)e 15.6 >250 >2 1.56
C. albicans B-311 >7.8 >250 16–32 >25
C. albicans 94-2181 >7.8 >250 >8–16 >12.5
C. parapsilosis (R)d 15.6–31.3 >250 0.5 >16
C. parapsilosis (S)e 15.6 >250 0.015 0.12
FILAMENTOUS FUNGI
F. graminearum B-4-5A 7.8 >125b nd nd
F. oxysporum 31.3 >250b nd nd
A. flavus 300 >250 0.125 nd
A. niger >150 >250 nd nd
B. alcada 15.6 nd
BACTERIA
E. coli TG1 125–250 1.95b
S. aureus ATCC 25923 250 <0.98b
M. luteus ATCC10240 62.5 1.95b
aMicrobroth dilution assays were performed at least twice, and each in triplicate.
bDetermined with kanamycin A; all others were determined with kanamycin B.
c not determined.
d (R) Resistant.
e(S) Sensitive.
an excitation wavelength of 488 nm and emission wavelength of
520 nm. Complete (100%) dye release was obtained by addition
of Triton X-100® (1%, vol/vol). The dye-leakage percentage was
calculated as follows: % dye leakage= 100×(F-F0)/(Ft-F0), where
F represents the fluorescence intensity 2min after K20 addition,
and F0 and Ft represent the fluorescence intensity without K20
and with Triton X-100®(1%, vol/vol), respectively (Zhang et al.,
2001).
CRYPTOCOCCOSIS PREVENTIVE MURINE LUNG INFECTION MODEL
In vivo efficacy of K20 treatment was evaluated in a proof of
concept study using preventive murine lung infection model as
previously described (Searles et al., 2013). For this study RAG−/−
mice lacking both T and B cells due to a defect in the recom-
bination antigen gene were obtained from Jackson Laboratories
(Bar Harbour, ME, USA) and maintained at the Montana State
University Animal Resource Center (Bozeman, MT, USA). The
studies conformed to NIH guidelines and were approved by
the Montana State University IACUC and biosafety committee
(approval number: (2014-17 and 027-2013). Three treatment
groups each consisting of five RAG−/− mice were compared.
Group A received one dose of 100μL of 200mg/L K20 in PBS
(10mMphosphate, 2.7mMKCl, and 137mMNaCl, pH 7), group
B received 100μL of 200mg/L K20 mixed with C. neoformans
H99 cells (5 × 103 cells/mL), and group C received cells mixed
in PBS only by intratracheal instillation. K20 doses averaged
0.824mg/kg body weight. Mice were monitored for signs of dis-
tress and their weights recorded daily over the course of infection.
Weight loss or gain was plotted as percent of weight change.
Mice were euthanized if weight loss exceeded 25%. At day 15
post-infection, lungs were removed, suspended in 5mL PBS and
homogenized by extrusion through a 100μm mesh steel screen.
Lung cryptococcal burden was assessed by plating 100μL of
the homogenized suspension onto yeast extract-peptone-dextrose
agar plates (26) at 1:10, 1:100, and 1:1000 dilutions in PBS,
incubated for 3 days, and colonies counted. For microscopic
examination, homogenates were suspended in 10mL of PBS and
a 1:20 dilution of the homogenate was spun onto glass slides using
a Cytospin 4 centrifuge (ThermoFisher, NJ, USA). Slides were
fixed in methanol for 3min followed by Diff-Quik™ (Siemens
Healthcare Diagnostics Inc. Newark, DE USA) staining for 3min
each in solution 1 and 2. Stained yeast cells were visualized with a
Nikon 80i Eclipse upright microscope as large purple colored cells
surrounded by opaque halos. The experiments were performed
twice. Data were statistically analyzed and P-values determined
by one-way (lung burden experiments) and Two-Way (weight
change experiments) ANOVA methods using GraphPad Prism
software (La Jolla, CA, USA).
RESULTS
IN VITRO ANTIFUNGAL AND ANTIBACTERIAL ACTIVITIES
K20 generally displayed antifungal activities against yeasts (e.g.,
S. cerevisiae strainW303C) and filamentous fungi (e.g., F. gramin-
earum B4-5A), but no or little activity against either Gram neg-
ative (e.g., E. coli TG1) or Gram-positive (e.g., S. aureus ATCC
6538) bacteria (Figure 2). In microbroth dilution assays with
RPMI 1640 medium, K20 inhibited the growth of most fungi
tested (Table 1). MICs ranged from 4 to 31.3mg/L for yeasts
and 7.8–300mg/L for filamentous fungi (Table 1). K20 MICs
with yeasts were uniformly higher than MICs achieved with itra-
conanzole and fluconazole except with azole resistant strains,
C. albicans strains 64124 and B-311 and C. tropicalis 95-41. MFC
values determined for C. albicans strains MYA 2876 and 64124
were equal to or 2-fold higher than the corresponding MIC val-
ues (data not shown). Among the yeasts tested, C. neoformans
strains were consistently the most susceptible to K20. Among
filamentous fungi tested, F. graminearum B4-5Awas themost sus-
ceptible to K20; A. flavus and A. niger were the least susceptible.
Bacterial species E. coli TG1, M. luteus ATCC10240 and S. aureus
ATCC6538 growing in LB medium were less susceptible to K20.
The antibacterial MICs were 65 to 125-fold higher than shown by
kanamycin A (Table 1).
ANTIFUNGAL CARRYOVER AND TIME-KILL ANALYSES
With C. neoformans H99, no antifungal carryover was observed
in the procedures used at 0.5, 1, and 2× the K20 MIC. The
time kill curves for K20 and C. neoformans H99, showed that
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FIGURE 2 | Antimicrobial activities of K20, FG08, and kanamycin A. Disk
agar diffusion assays show that K20 and FG08 are antifungal, but not
antibacterial. Kanamycin A is antibacterial, but not antifungal. Ten μL aliquots
of K20, FG08, and kanamycin A solutions were applied to paper disks (0.6 cm
diameter) on surfaces of PDA and LB agar at concentrations of 10 and
5mg/mL, respectively, and with spread-plated fungal (S. cerevisiae strain
W303C and F. graminearum B4-5A) and bacterial (E. coli TG1and S. aureus
ATCC 6538) cultures, respectively.
FIGURE 3 | Time kill curves for C. neoformans H99 exposed to K20.
Cultures were exposed to K20 at 2 mg/L (open triangles), 4mg/L (filled
circles), and 8 mg/L (open circles) or to no K20 (filled triangles).
the MIC level of K20 (4mg/L) reduced the CFU/mL by ≥2 log10
units (Figure 3). However, a 2× MIC level (8mg/L) of K20 was
required to achieve a fungicidal effect (100% killing). At 4mg/L
(1×MIC), K20 exhibited a fungistatic effect after 10 h incubation.
SHEEP ERYTHROCYTE HEMOLYSIS
K20 lysed <40% of sheep erythrocytes at 500mg/L (Figure 4)
a concentration that is >50-fold higher than the antifungal
MIC against C. neoformans H99. The HC50 value for K20
was >500mg/L. Kanamycin A did not show hemolytic activity
against sheep erythrocytes (data not shown).
ANIMAL CELL CYTOTOXICITY
K20 showed no or low toxicity against C8161.9 and NIH3T3 cells
at concentrations up to 250mg/L (Figure 5). The 50% inhibitory
FIGURE 4 | Hemolysis of sheep erythrocytes with various
concentrations of K20 after 1 h exposure at 37◦C (white bars). Controls
were exposure to Triton X-100® (1%, vol/vol) giving 100% hemolysis (black
bar) and no exposure to K20 (gray bar). The HC50 value is >500mg/L.
Standard deviation was used as the statistical parameter.
concentrations (IC50) of K20 for both C8161.9 and NIH3T3 cells
were > 500mg/L (Figure 5), and at least 31-fold higher than the
antifungal MIC against C. neoformansH99 (Table 1).
FLUORESCENT DYE UPTAKE
FITC dye was used to assess the membrane-perturbation effects
of K20 on the plasma membrane of C. neoformans H99 and
F. graminearum. FITC traverses cell surface membranes damaged
or permeabilized by external agents and concentrates intracellu-
larly to impart green fluorescence (Grilley et al., 1998; Mangoni
et al., 2004). For C. neoformansH99, K20 at 8 and 25mg/L caused
FITC staining of 64 and 100% of the cells, respectively, and <5%
when exposed to kanamycin A (50mg/L) (Figure 6). Untreated
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cells were negligibly stained (<2%). With F. graminearum B4-A5
hyphae, quantitation of the number of FITC stained cells was dif-
ficult because of its multinucleated cell structure. Qualitatively
however, 15.6 and 32mg/L K20 were observed to cause a high
FIGURE 5 | Toxicities of NIH3T3 mouse fibroblast cells (white bars) and
C8161.9 melanoma cells (gray bars) with 24h exposure to K20 at
various concentrations. Positive control (0% cell survival) was provided by
treatment with Triton X100® (1%, vol/vol) (black bar).
degree of FITC cell staining compared to exposure to 50mg/L
kanamycin A that gave essentially no visible staining of hyphae
(Figure 7).
SUV CALCEIN RELEASE
K20 showed dose- dependent release of calcein from model
lipid bilayer membrane SUVs that mimic fungal plasma mem-
branes. Within 15min, K20 at 31.2mg/L caused 30% calcein
leakage from SUVs composed of PC, PE, PI, and ergosterol
(5:4:1:2 by wt) and of PC and ergosterol (7:3 by wt) (Figure 8).
At 62.5mg/L, K20 caused 70–80% leakage from both types of
SUVs within 15min (Figure 8). SUVs without added K20 or
treated with Triton X-100® showed <10 or 100% calcein leakage,
respectively.
SUSCEPTIBILITY OF S. CEREVISIAE SPHINGOLIPID BIOSYNTHETIC
MUTANTS
Fungal cell surface sphingolipids influence the inhibitory activ-
ities of several amphiphilic, membrane interacting antifungal
compounds (Grilley et al., 1998; Stock et al., 2000; Thevissen
et al., 2003, 2012; Sugimoto et al., 2004). Among these com-
pounds is syringomycin E (Segre et al., 1989) which resembles
K20 in size (<1500 daltons) and structural features of hydrophilic
domains rich in hydroxyl and amino groups and hydrophobic
FIGURE 6 | Dose-dependent membrane perturbation effects of K20 on
C. neoformans H99. FITC dye uptake without (A1,A2) and with K20 (4mg/L)
(B1,B2), (8mg/L) (C1,C2), and (25mg/L) (D1,D2) exposure for 10min.
Bright-field images (A1,B1,C1,D1) are compared with fluorescence images
(A2,B2,C2,D2). Bar length is 10μm. (E1) Shows dose-dependent effects of
K20 on FITC dye uptake and effects of kanamycin A and no treatment Triton
X-100® (1%,vol/vol) gave 100% dye influx (data not shown). The error bars
show SD from analyses of 10 separate microscopic image fields randomly
selected from at least two separate experiments. Numbers above the range
bars indicate the number of cells analyzed.
www.frontiersin.org December 2014 | Volume 5 | Article 671 | 7
Shrestha et al. Antifungal amphiphilic aminoglycoside K20
FIGURE 7 | Dose-dependent membrane perturbation effects of K20 on
F. graminearum. FITC dye uptake without (A1,A2) and with K20 (7.8mg/L)
(B1,B2), (15.6mg/L) (C1,C2), and (32mg/L) (D1,D2) exposure for 10min.
Bright-field images (A1,B1,C1,D1) and fluorescence images (A2,B2,C2,D2).
Image a2 (no antimicrobial agent added) shows no fluorescent cells against
a fluorescent background. Bar length is 10μm. Triton X-100® (1%, vol/vol)
was assumed to give 100% dye influx (data not shown).
domains composed of alkyl chains. Fungal mutants with aber-
rations in sphingolipid structure or composition have been used
to reveal the roles of these lipids in antifungal mechanism of
action (Grilley et al., 1998; Stock et al., 2000; Ferket et al.,
2003; Thevissen et al., 2003, 2012). Therefore, syringomycin
E-resistant S. cerevisiae mutant strains with lipid defects caused
by single gene disruptions in specific sphingolipid biosynthetic
genes were examined for susceptibility to K20. Strain W303-
syr2 lacks the C4-hydroxyl group of the phytosphingosine
backbone, strain W303-elo3 has defective sphingolipids with
truncated very long fatty acyl chains, andW303-syr4 (ipt1) lacks
the most complex and abundant yeast sphingolipid, mannosyl-
diinositolphosphoryl-phytoceramide (MIP2C) (Grilley et al.,
1998; Stock et al., 2000). MICs against strains W303-syr2 and
W303-elo3 were 4–and 2-fold higher, respectively, compared
to those for isogenic wild-type strain W303C and strain W303-
syr4 (ipt1) (Table 2).
FIGURE 8 | Effect of K20 on calcein release from SUVs that mimic
fungal plasma membranes. Calcein released from SUVs made with
PC/PE/PI/ergosterol (5:4:1:2) (A) and PC/ergosterol (7:3) (B) were exposed
to K20 at 31.3mg/L (open circles), 62.5mg/L (open triangles), and 125mg/L
(open squares), kanamycin A at 62.5mg/L (filled triangles), and Triton
X-100® (1% vol/vol) (filled circles). Data were compiled from three separate
experiments. Standard deviation was used as the statistical parameter.
Table 2 | K20 susceptibilities of Saccharomyces cerevisiae
sphingolipid biosynthesis mutantsa.
Strain and genotype MIC (mg/L)b
W303C (MATα ade2 his3 leu2 trp1 ura3) 15.6
W303-syr2 (MATα ade2 his3 leu2 trp1 ura3 syr2
(sur2)::URA3)
62.5
W303-elo3 (MATα ade2 his3 leu2 trp1 ura3 elo2::HIS3) 31.3
W303-syr4 (ipt1)(MATα ade2 his3 leu2 trp1 ura3 syr4
(ipt1)::URA3
15.6
aValues are average of three assay determinations.
bMicrobroth dilution assays were conducted in RPMI 1640 medium.
EFFECT ON PREVENTIVE MURINE LUNG INFECTIVITY OF
C. NEOFORMANS H99
RAG−/− mice treated intratracheally with a mixture of K20 and
C. neoformans H99 cells maintained their body weights over
a 15-day infection time course. In contrast, mice treated with
C. neoformans H99 cells only showed weight losses starting at
day 10 post-infection (Figure 9). Lung fungal burdens of infected
mice were 4-fold (p ≤ 0.01) lower with K20 treatment in compar-
ison to untreated infected mice (Figure 10A). Stained images of
lung homogenates showed qualitatively decreased fungal burdens
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FIGURE 9 | Mean percent body weight change in groups of mice
receiving treatments of K20. Treatments with K20 were one dose/animal
of 100μL of 200mg/L K20 (filled circles), infected with one dose/animal of
100μL of C. neoformans H99 (5× 103 cells/mL) mixed with K20 (200mg/L)
(open triangles), and infected with 1 dose/animal of 100μL C. neoformans
H99 (5× 103 cells/mL) only (filled squares). Data were statistically analyzed
and P-values determined by One-Way ANOVA methods.
in mice infected with the mixture as compared to mice receiving
cells only (Figures 10B,C).
DISCUSSION
Unlike the difficult and complex synthesis of FG08, the syn-
thesis of K20 is simple and efficient. K20 synthesis involves
direct modification of kanamycin A and fewer synthetic steps.
Readily available reagents and large stockpiles of kanamycin A
(starting material) for its synthesis enhance the prospects for
its scalable production (laboratory scale of ∼300 g per batch)
and use. For both FG08 and K20, the antibacterial capabilities
of the corresponding kanamycin (kanamycin B for FG08 and
kanamycin A for K20) are simultaneously diminished with C8
alkyl chain attachment. Thus, a “switch“ occurs from bacterial to
fungal growth inhibition corresponding to non-alkylated and C8
alkylated kanamycin derivatives, respectively (Table 1). Lacking
antibacterial activities, K20 is not expected to promote bacte-
rial resistance with environmental or therapeutic use—a major
concern with the use of its parent kanamycin A (Fisher et al.,
2012).
Among the fungi species examined, Aspergillus species were
least susceptible to inhibition by K20 (Table 1). In contrast, all
yeasts tested were growth inhibited by K20 with C. neoformans
strains showing relatively high degrees of susceptibility. Fusarium
species, F. gramineaum and F. oxysporum were also highly suscep-
tible showing that K20 has broad spectrum antifungal inhibitory
capabilities that include filamentous fungi as well as yeast. The
generally higher MICs observed with K20 as opposed to the
lower MICs for azoles (Table 1) reflect the different modes of
action of these antifungal agents. The antifungal MICs observed
with K20 are similar to those achieved with recently reported
amphiphilic terephalamide–bisurea (Fukushima et al., 2013) and
lipopeptides (Makovitzki et al., 2008; Vallon-Eberhard et al.,
2008) that are antifungal when they assume high-aspect ratio
supramolecular assemblies that interact with target membranes.
The comparatively higher antifungal MICs of these amphiphiles
and possibly K20 are a consequence of polymeric assembly forma-
tion that precedes pore formation in membranes. Consistent with
its observed anti-cryptococcal activity, K20 significantly reduced
the infectivity of C. neoformans H99 in mice when administered
intratracheally together with the pathogen showing that even
a single initial treatment of K20 made a significant difference
(p = 0.01) in the propagation of the fungal pathogen. Finally,
it is noted that K20 inhibited well-known azole resistant strains
C. albicans ATCC 64124, C. albicans B-311, and C. tropicalis 95-41
with MICs that were lower than those of itraconazole and flu-
conazole (Table 1). Therefore, it appears that K20 is less subject to
the azole resistance mechanisms of C. albicans ATCC 64124 and
B-311 and C. tropicalis 95-41.
With an octanesulfonyl chain at the O-6′′ position, K20 is
an amphiphilic compound which in turn suggests interaction
with target cell membranes. Kanamycin A, K20’s parent com-
pound has an anti-bacterial mechanism of action that causes
protein translation misreading. K20’s rapid killing observed in
the time-kill curve studies (∼103-fold CFU decrease in 4 h
at 8mg/L) (Figure 3) suggests direct membrane action as the
basis for growth inhibition rather than indirect and slower
effects elicited by protein translational misreading or other indi-
rect effects that require cellular processing. Two approaches
were used to assess membrane-perturbation effects of K20.
Membrane-impermeable FITC uptake studies with cells and
calcein leakage studies conducted with model lipid bilayer
SUVs suggest that K20’s growth inhibitory effect is due to
direct and rapid effects on plasma membrane permeability.
These membrane perturbing effects resemble those previously
observed with K20’s predecessor, FG08 (Shrestha et al., 2013).
Therefore, the conversion of kanamycin A to K20 not only
alters the group of organisms it inhibits but also the mode of
action.
Altered K20 susceptibilities of yeast mutants with defec-
tive sphingolipids further support interaction with the fun-
gal plasma membrane. Yeast sphingolipids are mainly located
in plasma membranes, and they possess fungal-specific struc-
tural features that allow high densities of hydrogen and ionic
bonding sites for potential interaction with K20 (Stock et al.,
2000). S. cerevisiae strain W303-syr2 which lacks the sphin-
ganine backbone C4 hydroxyl group (Grilley et al., 1998) and
strain W303-elo3 with truncated fatty acid tails were 4 and
2-fold less sensitive to K20 compared to the isogenic wild-
type strain W303C (Table 2). These observations indicate a
role for sphinganine C4 hydroxylated sphingolipids in promot-
ing K20 action on the yeast plasma membrane. Yeast sphin-
golipids differ structurally from the mammalian sphingolipids
and also bacterial membrane lipids (Lester and Dickson, 1993).
The former have C4-hydroxylated sphinganine backbones and
many have inositolphosphate-containing head groups—features
not found in mammalian or bacterial cell lipids These struc-
tural differences may account for K20’s preferential targeting of
yeast and other fungi vs. mammalian and bacterial cells. An
absolute requirement for sphingolipids in K20 action, however,
is unlikely. SUVs used in this study lacked sphingolipids and
were still permeabilized by K20 (Figure 8). It is more likely
that combinations of lipids and other membrane components
that confer favorable interaction sites (such as, but not exclu-
sively, sphingolipids) are responsible for K20 binding and action.
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FIGURE 10 | Effect of K20 on C. neoformans H99 infectivity in a
RAG−/− mouse model. (A) Mouse lung fungal burden at day 15 after
infection with C. neoformans H99 cells mixed (black bar) or not mixed
(white bar) with K20. Fungal burdens were assessed by plating lung
homogenate suspensions for CFU determinations. Control treatment
with K20 and no cells (gray bar) showed no fungal burden.
∗∗∗ Indicates a p-value < 0.001 determined by One-Way ANOVA. Light
microscopic images of lung homogenates were prepared from
C. neoformans H99 infected mice with no K20 (B) and with K20 (C)
exposure. Methanol-fixed homogenates on glass slides were stained
with Diff-Quik™. Yeast cells were visible as large purple colored cells
surrounded by an opaque halo.
Similar sphingolipid-promoting, membrane pore forming modes
of action may be speculated for antifungal syringomycin E
(Grilley et al., 1998; Stock et al., 2000) and the plant defensin
DmAMP1 (Thevissen et al., 2000; Im et al., 2003). In contrast,
K20’s rapid permeability effect on non-sphingolipid containing
SUVs indicates that its mechanism of action differs from that
of antifungal plant defensin RsAPF2 (Thevissen et al., 2012).
RsAPF2 increases fungal membrane permeability by generat-
ing reactive oxygen species following binding to the sphin-
golipid glucosylceramide (Aerts et al., 2007; Thevissen et al.,
2012).
In conclusion, a novel aminoglycoside analog of kanamycin
A, K20, with an octanesulfonyl chain as a major structural fea-
ture, is a broad-spectrum antifungal that targets fungal plasma
membranes. K20 is not hemolytic, showed low mammalian cell
toxicities, and it reduced cryptococcal lung infectivity in a mouse
model. Because of these features, K20 is suggested as a lead com-
pound for a novel class of therapeutic antifungals as well as crop
protectants in agriculture.
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